An ongoing phase 2a study of RAP-219 involves adult patients with drug-resistant epilepsy who have an implanted responsive neurostimulation (RNS) device, allowing for real-time monitoring of intracranial EEG data.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on restless legs syndrome.

NeurologyLive® will provide in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

The SORT-IN-2 trial is a Phase 1b/2a proof-of-concept study evaluating the therapeutic potential of VES001, a novel oral treatment designed to target GRN mutations, which are the root cause of frontotemporal dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 10, 2024.

Between those infected and uninfected with COVID-19, investigators observed no differences in symptom trajectories, assessed through SymptoMScreen.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Russell Lebovitz, MD, PhD. [LISTEN TIME: 22 minutes]

Results from the open-label phase 1/2 study of tividenofusp alfa demonstrated positive effects on evidence-based surrogate end points in participants with Hunter syndrome.

Masoud Toloue, chief executive officer at Quanterix, and Nicholas J. Ashton, PhD, senior director of the Banner Health Fluid Biomarker Program, discussed the Simoa technology required to test for p-tau217, the expanding understanding of this biomarker, and the next steps for advancing this research.

The primary audience for the new appropriate use criteria is dementia specialists who dedicate a substantial portion of their clinical practice to treating patients with cognitive concerns.

Posdinemab, a monoclonal antibody that targets the mid-domain of Alzheimer disease-specific phosphorylated tau, is currently being investigated in a placebo-controlled phase 2b trial that employs a plasma biomarker as a screening tool.

The revised protocol merges the 6-month symptomatic and 18-month disease-modifying studies into a single trial with a 6-month symptomatic readout and a 12-month disease-modifying evaluation.

In a recent analysis, BrainCheck Access showed a high degree of alignment with the Montreal Cognitive Assessment in differentiating normal cognition, mild cognitive impairment, and dementia.

SGT-212 delivers full-length frataxin via MRI-guided intradentate nucleus infusion and intravenous administration to target mitochondrial dysfunction in neurons and cardiomyocytes, addressing both neurologic and cardiac symptoms.

The global Phase 3 trial aims to enroll ~150 patients with Dravet syndrome who have SCN1A variants, assessing zorevunersen's impact on seizure frequency, behavior, cognition, and safety over 60 weeks, with results expected by 2027.

The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai talked about how modern advances research have helped transition the understanding of multiple sclerosis from fixed phenotypes to a dynamic spectrum.

Lekha Rao, MD, an epileptologist at UCLA Health, discussed the challenges in diagnosing D/EE-SWAS, the importance of early EEG, and the need for greater awareness around this rare and complex epileptic condition.

Despite not meeting its primary and key secondary end points, an exploratory high dose cohort of fosigotifator demonstrated promising results on end points of muscle strength.

Over a 24-week period, DNL343 failed to distinguish itself from placebo on the primary end point of ALSFRS-R, as well as on other secondary end points of muscle strength and respiratory function.

Babitha Haridas, MD, MBBS, a pediatric epileptologist at Johns Hopkins Medicine, discussed the complexities with managing status epilepticus in Lennox-Gastaut syndrome, focusing on the importance of identifying triggers early in their condition.

The Delphi-MD platform is designed for nerve stimulation in diagnostic applications, offering clinicians a tool to support objective and personalized treatment approaches in brain health.

Most participants showed improvements in motor function, with 61% achieving a clinically meaningful increase in HFMSE scores by week 52 and 41% achieving similar gains in RULM scores.

The ACCORD-2 trial demonstrated a significant reduction in overall worsening compared to placebo, while the ADVANCE-2 trial showed numerically greater improvements without reaching statistical significance.

Results from Vigil Neuroscience’s ongoing phase 1 trial of VG-3927 in healthy volunteers supported the continued development of the therapy as a potential once-daily oral treatment for Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.